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Objective: The atherosclerotic plaque that is vulnerable to rupture and to superimposed thrombosis is
mainly represented by a thin-cap ﬁbroatheroma with or without ulceration/thrombosis and inﬂamma-
tory inﬁltrates. Total serum gamma-glutamyltransferase (GGT) activity is an independent predictor for
cardiovascular events. Four GGT fractions have been identiﬁed in plasma and only one of them (b-GGT) in
atherosclerotic plaques, but the possible role of GGT in plaque pathophysiology has not been assessed
yet. We investigated the relationships between plaque b-GGT activity and the histological features of
plaque vulnerability. Methods and results: Plaque GGT activity was investigated in 65 patients under-
going carotid endarterectomy; plaques were histologically characterized and immunostained for GGT.
Intra-plaque total and fractional GGT activity was determined by a cost-effective test of molecular size
exclusion chromatography, and compared with histological markers of plaque vulnerability. Plaque
cholesterol content was also measured by chromatography. b-GGT was the only fraction detected within
the atherosclerotic plaques and intra-plaque b-GGT activity correlated to plaque cholesterol content
(r ¼ 0.667, P < 0.0001), plasma b-GGT and f-GGT fractions (r ¼ 0.249; r ¼ 0.298, both P < 0.05). Higher b-
GGT activity was found in thin-cap ﬁbroatheromas and it was associated to histological markers of
vulnerable plaques, i.e., larger necrotic areas, greater macrophage inﬁltration and higher cholesterol
content (P < 0.05). Conclusions: intra-plaque b-GGT activity correlates with the histological markers of
vulnerable plaque and with plasma b-GGT in human carotid atherosclerosis; these data support the
possible role of b-GGT in clinically signiﬁcant atherosclerotic disease.
© 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Cardiovascular diseases are leading causes of death, the social
and economic burden of atherosclerosis increasing in the last de-
cades together with population ageing [1]. Atherosclerosis is a
progressive disease; cellular and molecular alterations within the
arterial wall lead to lumen narrowing and/or to plaque rupturewithnt, Pisa University Hospital,
lapucci@libero.it (A. Pucci).
work.
rved.superimposed acute thrombosis, such complicated plaques repre-
senting the antecedents for cardiovascular events [2e5].
The atherosclerotic plaques that are vulnerable to rupture and to
thrombosis show well deﬁned histological features [2,3,6e8].
Morbidity and mortality from atherosclerosis is largely due to
vulnerable plaques, i.e., type IVeVI lesions according to the Amer-
ican Heart Association (AHA) classiﬁcation, corresponding to thin-
cap ﬁbroatheromas with or without ulceration/ﬁssuration showing
a large necrotic core and abundant inﬂammatory inﬁltrates, mainly
constituted by macrophages [9e11]. Conversely, stable lesions
usually correspond to predominantly ﬁbrous/ﬁbrocalciﬁc plaques
and to thick-cap ﬁbroatheromas with low or absent inﬂammation,
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bosis [8e12].
The evolution of the atherosclerotic plaque towards stabilization
or vulnerability is not completely understood so far [13], the search
for in vivo biomarkers of plaque instability and subsequent life-
threatening complications representing a major challenge of
modern medicine [14e18].
During the last decade, total serum gamma-glutamyltransferase
(GGT) activity has been recognized as a risk factor for both coronary
and cerebrovascular events in unselected populations [19,20] as
well as in patients with diagnosed coronary artery disease [21]. Its
predictive value is independent and additive, as compared to other
established markers, and independent from liver disease or alcohol
consumption [17,19,21].
As to the possible role of GGT in plaque instability, its active form
has been previously shown to co-localize with inﬂammatory cell
inﬁltrates and peroxidized low-density lipoprotein (LDL) in both
coronary and carotid plaques [16,21,22]. The GGT activity has been
hypothesized to exert a direct pro-oxidant activity, eliciting the
production of reactive oxygen species from cystenylglycine
(CysGly) moieties via its catalytic activity on extracellular gluta-
thione [23e25], the occurrence of GGT-mediated redox reactions
having been demonstrated within the plaque [26]. Recently, four
plasma GGT fractions have been identiﬁed by molecular size
exclusion chromatography, i.e., b-GGT, m-GGT and s-GGT (that very
likely represent >2000, 940 and 140 kDa, respectively, lipoprotein-
bound molecular masses) plus the 70 kDa free fraction f-GGT
[27,28]; only the highest molecular weight fraction b-GGT, has been
found within atherosclerotic plaques by our group [26].
The aim of this study is to evaluate the possible relationships
between intra-plaque b-GGT content, localization and activity and
the histological features of plaque vulnerability in carotid athero-
sclerosis; in order to better understand the pathophysiology of
high-risk plaque formation. Plasma GGT fractions are also investi-
gated in the same patients.
2. Materials and methods
2.1. Study population
We investigated 65 consecutive patients undergoing carotid
endarterectomy at the General and Vascular Surgery (University
Hospital, Pisa, Italy). Since endarterectomy is recommended in
patients with severe carotid artery stenosis (>70%), even in absence
of neurological symptoms, the major part of this cohort was
constituted by asymptomatic patients (n ¼ 50), while 15 patients
showed neurological symptoms. The indication for endarterectomy
was based on the recommendations published by the Asymptom-
atic Carotid Surgery Trail and on the European Carotid Surgery Trail
and the North American Symptomatic Carotid Endarterectomy Trail
[29e32].
In all cases, baseline data were obtained by clinical ﬁles,
including history of vascular disease, cardiovascular risk factors and
medication use. Patients were on appropriate therapy with lipid-
and/or glucose-lowering drugs, anti-coagulant or antiplatelet
agents, anti-hypertensive drugs, according to current guidelines.
Carotid stenosis severity was evaluated by ultrasound analysis.
Hypertension was deﬁned as systolic blood pressure 140 mmHg
and/or a diastolic pressure 90 mmHg, with or without anti-
hypertensive treatment at the time of endarterectomy. Diabetes
mellitus was diagnosed in patients with fasting blood glucose
>126 mg/dL, and/or current oral or insulin treatment. Dyslipidemia
was diagnosed as total cholesterol level >200 mg/dL (>5.18 mmol/
L) and/or serum triglycerides 150 mg/dL (>1.70 mmol/L), and/or
current statin/ﬁbrate treatment.The study was approved by the Institutional Ethics Committee,
and conformed to the Declaration of Helsinki, and patients gave the
informed consent.
Standard assay of all blood tests were simultaneously performed
according to the standard clinical laboratory procedures by auto-
mated analysers, plasma high sensitivity C-reactive protein (hs-
CRP) was determined on Synchron CX instrument (Beckman, USA).
2.2. Tissue sampling
Surgically excised carotid plaques were collected on ice and
dissected into 5-mm segments. Adjacent segments having the
greatest plaque area and representing the culprit lesion, were ﬁxed
in 10% buffered formalin or in 70% cold ethanol and parafﬁn-
embedded for histological analyses, and frozen at 20 C after
being rinsed in cold Dulbecco's phosphate buffer for biochemical
investigations, respectively. In a sub-group of these patients
(N ¼ 20) with adequate plaque volume, a third segment of the
plaque was frozen at 20 C in Optimal Cutting Temperature (OCT)
medium.
Plaque fragmentation due to the surgical procedure was mini-
mal, allowing histological analysis in all cases.
2.3. Histopathological investigations
Serial 3 mm parafﬁn sections were stained with haematoxylin-
eosin andMasson's trichromemethod. Immunohistochemistry was
performed on adjacent parafﬁn-embedded sections. Macrophages
were identiﬁed by immunoperoxidase staining by using a speciﬁc
monoclonal antibody raised against CD68 antigen, and endothelial
cells by the antibody against CD31 antigen (Dakopatts, Glostrup,
Denmark); immunoreactions were visualized by 3-
diaminobenzidine substrate. GGT immunostaining was performed
by using a previously characterized polyclonal antibody directed
against the heavy chain of human GGT antigen at the appropriate
dilution (1:1600) [33].
GGT enzymatic activity was evaluated both on 5 mm OCT
embedded cryostat sections and on serial 3 mm parafﬁn sections
obtained from plaques ﬁxed in ethanol. The histochemical reaction
was performed by using the speciﬁc substrate gamma-glutamyl-4-
methoxy-2-naphtylamide and the diazonium salt Fast Blue BB as a
chromogen [34].
The tissue areas constituted by lipidic core, ﬁbrous tissue,
calciﬁcation or immunostained for CD68 were automatically
measured by a grey scale detection method with a ﬁxed threshold
by a computer-based morphometry software (J-Image, NIH,
Bethesda, Maryland; USA).
2.4. Histological characterization of plaques
The plaques were histologically classiﬁed according to the
American Heart Association (AHA) scheme [2,3] and, for the aim of
the study, were categorized as stable or vulnerable plaques [7,9].
The vulnerable plaques were deﬁned by the presence of a thin cap
ﬁbroatheroma, i.e., a ﬁbrous cap <165 mm thick, whereas the stable
plaques corresponded to predominantly ﬁbrous lesions with a
ﬁbrous cap 165 mm thick.
To investigate possible relationships between plaque histology
and intra-plaque b-GGT, the plaque components were categorized
according to the following scoring system: a) necrotic core, score
0 (absent), 1 (low, i.e., representing up to 25% of the total plaque
area), 2 (medium, >25e50%) or 3 (high, >50%); b) ﬁbrous tissue,
score 1 (low, up to 30%), 2 (medium, >30e60%) or 3 (high, >60%); c)
calciﬁcations, score 0 (absent), 1 (low, up to 15%), 2 (medium,
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0 (absent), 1 (low, up to 5%), 2 (medium, >5e10%) or 3 (high, >10%).2.5. Homogenates of atherosclerotic lesions
Portions of plaque were snap-frozen in liquid nitrogen, me-
chanically disrupted and homogenized in 5% volume of cold hy-
potonic buffer (PBS diluted 10 folds) using a Potter homogenizer.
Crude homogenates were centrifuged at 1000 g, 5 min, 4 C and the
supernatant was further centrifuged 10,000 g,15min, 4 C, the ﬁnal
sample was then used for fractional GGT analysis.Table 1
Patients' characteristics.
Subjects (n ¼ 65)
Age, y 74 (68e79)
Males, n (%) 46 (70.8)
BMI, kg/m2 26.8 (24.4e27.8)
Diabetes, n (%) 25 (38.5)
Hypertension, n (%) 56 (86.2)
Dyslipidemia, n (%) 55 (84.6)2.6. Fractional GGT analysis
Fractional GGT analysis was performed as previously described
[27,28] using an FPLC (fast protein liquid chromatography) system
(AKTA puriﬁer, GE Healthcare Europe, Milan, Italy) equipped with a
gel-ﬁltration column (Superose 6 HR 10/300 GL, GE Healthcare
Europe) and a ﬂuorescence detector (Jasco FP- 2020, Jasco Europe,
Lecco, Italy). Plaque homogenates and plasma samples (0.02 ml)
were injected in the gel-ﬁltration column, after being ﬁlteredwith a
0.45 mm polyvinylidene ﬂuoride Millipore ﬁlter. GGT activity was
measured using gamma-glutamyl-7-amido-4-methylcoumarin
(Nova Chimica, Milan, Italy) as substrate (0.03 mmol/L, ﬁnal con-
centration) and glycylglycine (5.4 mmol/L, ﬁnal concentration) as
acceptor of the transpeptidation reaction. The ﬂuorescence detec-
tor operating at excitation/emission wavelengths of 380/440 nm
detected the amino-4-methylcoumarin signal; the intensity of the
ﬂuorescence signal was expressed in arbitrary ﬂuorescence units.
Under this reaction conditions, area under curve is proportional
to GGT activity. Total area, between 10 and 25 mL elution volume,
and fractional GGT area was calculated by a MatLab program
(Version 7 MathWorks, Inc.) to resolve overlapping peaks; the
curve ﬁtting was conducted with a nonlinear least-squares mini-
mization algorithm using four exponentially modiﬁed Gaussian
(EMG) curves. The reaction was calibrated analysing plasma sam-
ples with known total GGT activity (standards). The slope of the
calibration curve was used to convert total and fractional GGT area
to U/L. The sum of fractional GGT activity represents on average the
99% of total GGT activity. A 4.5 mmol/L stock solution of gamma-
glutamyl-7-amido-4-methylcoumarinwas prepared in ethanol 40%
v/v containing 0.01 N NaOH and stored at 20 C. This solutionwas
diluted 25-fold into 0.25 M TriseHCl buffer pH 8.5 (25 C) daily.Cerebrovascular symptoms, n (%) 15 (23.1)
Ischaemic heart disease, n (%) 19 (29.2)
Glucose, mg/dL 107 (98e121)
Creatinine, mg/dL 1.1 (0.9e1.3)
Albumine, g/dL 4.4 (4.2e4.6)
Bilirubin, mg/dL 0.4 (0.3e0.5)
Cholesterol, mg/dL 191 (166e213)
HDL, mg/dL 45 (43e55)
LDL, mg/dL 113 (100e132)
Triglycerides, mg/dL 125 (99e172)
AST, U/L 20 (16e25)
ALT, U/L 19 (13e26)
ALP, U/L 79 (64e100)2.7. Cholesterol analysis by high-performance gel ﬁltration
chromatography
Distribution proﬁle of the cholesterol in plaque homogenates
was obtained by the fractional GGT analysis method, but a
commercially available reagent for total cholesterol determination
(GiesseDiagnostic, Rome, Italy) was used as post-injected reagent.
Reaction product was detected by recording the absorbance at
510 nm.Leucocytes, 103/mL 7.4 (6.5e8.6)
Fibrinogen, mg/dL 396 (366e432)
hs-CRP, mg/dL 0.3 (0.1e0.6)
Total GGT, U/L 24.97 (19.06e38.77)
b-GGT, U/L 2.84 (1.80e5.79)
m-GGT, U/L 0.74 (0.40e1.24)
s-GGT, U/L 9.20 (5.26e16.82)
f-GGT, U/L 13.21 (10.09e15.02)
Data are reported as median (25the75th percentiles). BMI, body mass index; HDL,
high density lipoprotein, LDL low density lipoprotein; AST, aspartate aminotrans-
ferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-
glutamyltransferase; hs-CRP, high sensitivity C-reactive protein.2.8. Statistical analysis
Continuous variables are expressed as mean ± standard devia-
tion (SD), or median (25the75th percentile), as appropriate. Vari-
ables with known skewed distributions were natural
logarithmically transformed before further analysis. Statistical
analysis of data was performed by Student's t-test and Pearson's
correlation analysis. A P value <0.05 was considered to indicate
signiﬁcance.3. Results
3.1. Population characteristics
Study patients were elderly (age 73.5 ± 8.1 years, 46 males) and
showed, as expected, a high prevalence of arterial hypertension
(86%) and/or dyslipidemia (85%) with overweight in 43% patients,
diabetes in 39%, concomitant ischaemic heart disease in 29%, cur-
rent smoking habit in 22%. Detailed clinical and biohumoral char-
acteristics of the study population, including values related with
analysis of total and fractional plasma GGT activity are reported in
Table 1.3.2. Intra-plaque GGT and correlations with plasma GGT fractions
Plaque homogenates displayed GGT activity in all but one case,
corresponding to an exclusively ﬁbrous plaque without necrotic
core.
Total GGT activity of plaque homogenates ranged between 7.6
and 126.4 mU/g tissue (43.8 ± 27.3). A unique distinct peak of b-
GGT was identiﬁed at fractional GGT analysis (Fig. 1), with a mean
activity of 15.4 ± 10.7 mU/g tissue (range 2.6e46.7 mU/g tissue).
Intra-plaque b-GGT activity was shown to correlate with intra-
plaque total cholesterol content, as well as with plasma b- and f-
GGT fractions, and ﬁbrinogen (Table 2). No correlation was found
between intra-plaque b-GGT and serum triglyceride, fasting
glucose, leucocytes or hs-CRP (Table 2). No association was found
between intra-plaque b-GGT levels and the extent of lumen nar-
rowing at echo-Doppler examination (stenosis <80%,
13.8 ± 9.3 mU/g tissue; stenosis 80%: 15.8 ± 10.8 mU/g tissue;
P ¼ 0.4987).
A residual GGT activity within the plaques, without discrete
peaks (Fig. 1), was detected (28.4 ± 17.6 mU/g tissue, range
Fig. 1. Representative elution proﬁle of GGT activity in plaque homogenate (contin-
uous line) and plasma (dashed line) obtained from the same patient (C28). Elution
proﬁle was obtained by molecular exclusion chromatography, and GGT activity was
detected by an on-line post-column reaction in presence of a ﬂuorescent substrate,
gGluAMC [28].
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intra-plaque cholesterol and plasma f-GGT fraction only (Table 2).
3.3. Plaque histology and GGT
The total mean area of the examined endarterectomy specimens
was 65.67 ± 8.27 mm2. According to the AHA histological classiﬁ-
cation of atherosclerosis [2,3], 20 (32%), 10 (15%), and 1 plaques
were deﬁned as type Va, Vb, and Vc, respectively, whereas 12 (18%),
14, (22%), 3, (5%) and 5 (8%) were categorized as type VIa, VIb, VIc
and VIabc, respectively. No type IeIV plaque was found.
A detailed histopathological characterization of vulnerability
features is reported in Supplemental data Table 1. Thirty-four out of
41 vulnerable plaques (87%) were type VI according to AHA clas-
siﬁcation, 7 (13%) were type V, while all 24 stable plaques (100%)
were type V lesions.
As expected, thin-cap ﬁbroatheromas (n ¼ 41, 63%) were char-
acterized by large necrotic core and high macrophage inﬁltration
(Fig. 2, panels AeC), whereas stable plaques (n ¼ 24, 37%) showed a
thick-cap ﬁbroatheroma, small necrotic cores and light macrophage
inﬁltration (Fig. 2, panels DeF) in all but one case with exclusively
ﬁbrous content and no necrotic core.Table 2
Bivariate correlation analysis between intra-plaque b-GGT and residual GGT activity
(mU/mg tissue), intra-plaque cholesterol content (mg/g tissue) and plasma analytes.
Intra-plaque b-GGT Intra-plaque
residual GGT
r P r P
Intra-plaque cholesterol 0.667 <0.0001 0.469 0.0003
hs-CRP 0.084 0.5143 0.018 0.8875
Fibrinogen 0.281 0.0320 0.327 0.0124
Leucocytes 0.080 0.5484 0.073 0.5840
Fasting glucose 0.058 0.6591 0.025 0.8468
Triglycerides 0.027 0.8454 0.080 0.5649
Total GGT 0.242 0.0582 0.241 0.0553
b-GGT 0.249 0.0470 0.206 0.1033
m-GGT 0.203 0.1152 0.187 0.1390
s-GGT 0.169 0.1939 0.180 0.1543
f-GGT 0.298 0.0170 0.341 0.0058
Data are reported as Pearson correlation coefﬁcients. hs-CRP, high sensitivity C-
reactive protein; GGT, gamma-glutamyltransferase. Intra-plaque residual GGT ac-
tivity was calculated as the difference between intra-plaque total GGT and b-GGT
activity.Immunohistochemical (Fig. 2) and histoenzymatic staining
showed the presence of variable amounts of immunoreactive and
catalytically active GGT, mainly localized to plaque areas corre-
sponding to necrotic core, foamy macrophage-rich sites, and, to a
lesser extent, to the endothelial lumen layer and/or to intra-plaque
neoangiogenetic vessels (Supplemental Figs. 1 and 2).
As compared to thick-cap plaques, thin-cap ﬁbroatheromas
showed signiﬁcantly higher (P < 0.05) intra-plaque GGT activity,
both as b-GGT (16.8 ± 10.0 vs. 13.0 ± 11.7 mU/g tissue, Fig. 3) and
residual GGT activity (31.4 ± 17.0 vs. 23.1 ± 17.8 mU/g tissue,
Supplemental data Fig. 3) and higher cholesterol content
(0.24 ± 0.21 vs. 0.13 ± 0.08 mg/g tissue, P < 0.05). As to the other
histological features (Fig. 3), plaques with larger necrotic cores
(score 3) showed a higher intra-plaque b-GGT activity as compared
to those with small/medium necrotic core (scores 0e2; 17.2 ± 16.2
vs. 12.3 ± 10.4 mU/g tissue, P < 0.036). Plaque b-GGT activity was
also higher in presence of a high vs. low macrophage inﬁltration
(score 2e3 vs. score 0e1; 16.7 ± 11.0 vs. 11.1 ± 8.8 mU/g tissue,
P < 0.025). Either ﬁbrous component and calcium content were
negatively associated with intra-plaque b-GGT activity, the lowest
ﬁbrous tissue score 1 corresponding to higher b-GGT activity as
compared to higher ﬁbrous scores (2e3; 16.8 ± 10.3 vs.
11.7 ± 11.3 mU/g tissue, P < 0.023), and the highest calcium content
(scores 2e3) showing lower levels of b-GGT as compared to scores
0e1 (10.5 ± 10.4 vs. 17.4 ± 10.3 mU/g tissue, P < 0.01).
As to intra-plaque residual GGT activity, signiﬁcant lower levels
were found only in plaques with higher calcium content (21.9 ± 17.2
vs. 30.9 ± 17.3 mU/g tissue, P < 0.05), whereas no association was
found with necrotic core, macrophage inﬁltration and ﬁbrous
component (Supplemental Fig. 3). Finally, no correlation was found
between all above mentioned plaque histological features and hs-
CRP circulating levels.
Plasma total and fractional GGT activity showed no statistically
signiﬁcant relationship with histological plaque features of insta-
bility (data not shown).
4. Discussion
This is the ﬁrst study demonstrating that a speciﬁcally higher
extent and activity of intra-plaque b-GGT is characteristic of pla-
ques with the histological features of vulnerability, i.e., thin-cap
ﬁbroatheromas with large necrotic core and high macrophage
inﬁltration [7,9] that have been previously shown to be associated
with adverse clinical events on either in vivo (i.e., on carotid end-
arterectomies) and post-mortem studies [6,7,9]. Accordingly to the
AHA histological classiﬁcation of atherosclerosis, most vulnerable
plaques (87%) of the present study corresponded to type VI
complicated lesions [2,3]. Conversely, intra-plaque b-GGT was
inversely correlated with ﬁbrosis and microcalciﬁcations,
commonly observed in stable plaques in either carotid or coronary
arteries [10,12].
Several clinical and population studies have shown that serum
GGTactivity independently predicts the risk of acute cardiovascular
events associated with atherosclerosis, including stroke
[19e21,35,36]. However, the relationship between plaque GGT ac-
tivity and histological features of plaque vulnerability has never
been previously established. GGT is the main determinant of the
extracellular glutathione hydrolysis [37] that causes the release of
the dipeptide CysGly. The reactive thiol of CysGly may cause the
reduction of ferric Fe(III) to ferrous iron Fe(II), starting a redox-
cycling process with subsequent production of the reactive oxy-
gen species superoxide anion and hydrogen peroxide [37]. These
reactions could take place in the necrotic core of the plaque, where
both GGT [22,25,26] and iron are present at adequate concentra-
tions [38]. In fact, in a previous study, we showed that in carotid
Fig. 2. A thin cap ﬁbroatheroma without ulceration (A) shows higher immunoreactivity for GGT (B) and for CD68 macrophage antigen (C) than a plaque with a thick ﬁbrous cap (D)
with GGT (E) immunoreactivity limited to few cells and no detectable CD68 immunostaining (F). In the thin cap ﬁbroatheroma, either endothelial layer and macrophage-rich areas
shows GGT immunostaining that in the thick ﬁbrous cap is localized to the endothelial layer and to few interstitial cells (A, D: Masson's trichrome staining; B, C, E, F: Immuno-
peroxidase with Haematoxylin counterstaining. Original magniﬁcation: 20).
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oxidant reactions catalysed by GGT, including protein-linked
CysGly [26], the biochemical marker which documents that GGT-
mediated redox reactions have taken place [26,39].
Redox events can play a relevant role in several processes
favouring atherosclerotic plaque destabilization and rupture, i.e.,
LDL oxidation [23], activation of matrix metalloproteinase expres-
sion/activity and TIMP inhibition [25,40,41], matrix remodelling
and ﬁbrous cap thinning. Our study shows that intra-plaque b-GGT
activity correlates with circulating b- and f-GGT level. This obser-
vation adds to ﬁndings from population studies showing the
highest predictive value of serum total GGT activity for cardiovas-
cular events at mediumehigh levels within normal 25e50 U/L
reference range [17,20,21]. Metabolic and cardiovascular risk
markers are important correlates of GGT fractions, in particular of
b-GGT in healthy subjects [42] and in Framingham population [43].
It is noteworthy that non-alcoholic fatty liver disease, a component
of the metabolic syndrome which is associated to increased car-
diovascular risk [44], seems to be a rather speciﬁc cause of plasma
b-GGT increase in blood [45], while alcohol abuse and liver diseases
are more speciﬁcally associated with s-GGT elevation [46].Interestingly we observed that fractional GGT analysis identiﬁed
a unique distinct peak of b-GGT activity within plaque homoge-
nates, thus raising the issue of the intra-plaque GGT-activity origin.
The 2000 kDa molecular weight of b-GGT corresponds to that of
microparticles or exosomes and could allow its deposition within
the plaque from the bloodstream through damaged endothelium in
subjects with elevated plasma b-GGT level, while its ability to
oxidize LDL [23] and its chemokine properties [47] could explain its
co-localization with CD68þmacrophages. The association between
intra-plaque b-GGT and CD68þmacrophage inﬁltration might even
in part depend upon the ability of activated macrophages to release
b-GGT, as already shown for neutrophils [48]. Furthermore, we
observed a signiﬁcant correlation between intra-plaque b-GGT and
cholesterol plaque content. Either cholesterol increase and
macrophage inﬁltration may lead to endothelial damage from
oxidized-LDL, which might in turn facilitate plasma b-GGT passage
into the plaque. Thus plaque GGT may derive both from insudation
of plasma b-GGT as well as from endogenous synthesis by cellular
elements of likely inﬂammatory nature. The major candidate are
the macrophages that are known to express GGT activity [49] and
that might be the source of the mRNA transcribed from GGT-I gene
Fig. 3. Intra-plaque b-GGT activity distribution according to the histopathological features. Cap thickness: thick (n ¼ 24), thin and ulcerated (n ¼ 41). Necrotic core: score 0e2
(absent up to medium, n ¼ 24), large (3; n¼ 41). CD68þmacrophage inﬁltration: score 0e1 (absent-low, n ¼ 16), 2e3 (mediumehigh, n ¼ 49). Fibrous tissue: score 0e1 (absent-low,
n ¼ 47), 2e3 (mediumehigh, n ¼ 18). Student's t test has been performed on ln-transformed data. *P < 0.05.
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aimed to elucidate how differentiation from monocytes, to mac-
rophages and to foam cells inﬂuence GGT expression. The study of
the properties of GGT expressed by macrophages will allow the
quantiﬁcation of the cellular and plasma contribution to intra-
plaque GGT activity.
Finally, the correlation between intra-plaque GGT activity and
plasma f-GGT suggests that also this fraction might inﬁltrate into
plaque through the damaged endothelium.
It is noteworthy that the intra-plaque residual GGT activity, even
if greater then intra-plaque b-GGT activity, showed lesser associa-
tion with histological features of plaque vulnerability, thus
strengthening the role of b-GGT activity in plaque vulnerability.
In the present series including patients undergoing elective
carotid endarterectomy, independently from presence of symp-
toms (observed only in a minority of patients, i.e., 15/65 subjects,
23%) we did not observe any correlation between serum CRP levels
and intra-plaque or circulating GGT levels; CRP is considered a non-
speciﬁc predictive marker of cardiovascular events and previous
studies have shown that serum CRP and serum GGT are indepen-
dent and additive predictors of cardiovascular events [17]. CRP and
GGT might be related to different aspects of the atherosclerotic
disease; elevated serum CRP levels appear more likely to indicate
the systemic nature of progressive atherosclerotic disease rather
than uncovering the presence of a single vulnerable lesion [50],
whereas GGT could represent an index of on-going oxidative stress.
Limits of the study. This study did not investigate the possible
relationships between b-GGT and symptomatic carotid artery dis-
ease; the selection criteria of this series (i.e., patients undergoing
elective carotid endarterectomy on the basis of imaging results and
of clinical evaluation) and the small number of patients with
symptomatic disease (N ¼ 15/65, 23%) did not allow us to look for
possible correlations between intra-plaque b-GGT activity, plaque
histological features and cerebrovascular symptoms.
In conclusion, intra-plaque b-GGT was associated to histological
features of vulnerable plaques in carotid endarterectomies, and to
circulating b-GGT in the same patients. b-GGT fraction might play arole in atherosclerosis progression, and, rather than total GGT itself,
might be related to the previously observed risk of acute cardio-
vascular events. On the basis of these results, future studies will be
aimed to recruit a larger cohort for a prospective study in order to
deepen the clinical meaning of circulating b-GGT in atherosclerotic
disease; future applications for novel imaging monitoring of plaque
instability might as well be evaluated.
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